Nivolumab ELISA Kit (ab237651)
Key features and details
- Sensitivity: 10 ng/ml
- Range: 30 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Nivolumab ELISA Kit
See all Nivolumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
10 ng/ml -
Range
30 ng/ml - 3000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Nivolumab ELISA kit ab237651 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Nivolumab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4382 BioSim™ Nivolumab (Human) ELISA Kit. E4382-100 is the same size as the 96 test size of ab237651.
-
Platform
Microplate (12 x 8 well strips)
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 x 96 tests 96 tests Micro ELISA Plate 1 unit 1 unit Nivolumab Standard S1 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S2 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S3 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S4 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S5 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S6 1 x 0.3ml 1 x 0.3ml Nivolumab Standard S7 1 x 0.3ml 1 x 0.3ml Assay Buffer 2 x 50ml 2 x 50ml HRP-conjugate Probe 1 x 12ml 1 x 12ml TMB substrate 1 x 12ml 1 x 12ml Stop Solution 1 x 12ml 1 x 12ml Wash buffer (20X) 1 x 50ml 1 x 50ml Plate sealers 2 units 2 units -
Relevance
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models. -
Alternative names
- Opdivo
Images
-
Example of Nivolumab standard curve
Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab237651 has not yet been referenced specifically in any publications.